10.15.26 -- The Orange Book's Blind Spot: Process Stability And Capability

Choosing a CMO is a strategic decision that shapes long‑term quality and scalability. Discover how a focused framework helps teams identify partners that can adapt and support growing portfolios.

Chromatography scale-up depends on aligning different factors. Learn which factors can help maintain process consistency, manage risk, and support the transition from development to manufacturing.

Targeted impurity identification and purification redesign dramatically improved yield, reduced process complexity, and enabled reliable API supply for Phase II clinical development.

Head pressure affects how material moves from the hopper into the tablet press. What is head pressure in your hopper and how does it relate to tablet press performance?

CDMO guide on environmental monitoring, media fills, and QC to prove sterility assurance in aseptic manufacturing—key elements of the Contamination Control Strategy beyond facility design.

Gain practical perspective on emerging capabilities, common sponsor challenges, and what will matter most as the CDMO landscape continues to evolve.

Data integrity in pharmaceutical QC labs is critical for product safety. Take a look at digital solutions to improve traceability, reduce paperwork, and enhance workflows.

Three studies focus on a product designed to address unmet needs in subcutaneous drug therapies for chronic diseases, including sterilization methods and a Human Factors evaluation.

See how disciplined planning, technical expertise and close collaboration kept a complex softgel transfer on track despite equipment delays, regulatory demands, and an aggressive timeline.

Examine the regulatory complexity of combination products and learn how holistic development strategies, early equipment decisions, and representative clinical supply reduce risk and costs.

Selecting the right CCIT strategy starts with defining leakage risks and defect limits. Matching test methods to package design supports compliance, lifecycle needs, and patient safety.

Establishing a robust, risk-based CAPA system prevents recurring process deviations, satisfies ICH Q10 guidelines, and ensures standing inspection readiness.

Particulate-related recalls account for 37% of US FDA injectable drug actions, and evolving FDA and EU GMP requirements are raising the compliance bar for manufacturers.

Expression of inclusion bodies has historically suffered a bad reputation in the industry. So, how do these two routes, soluble and insoluble, compare in terms of their advantages and challenges?

Delve into how Blow/Fill/Seal technology supports contamination control, reduces operator risk, and meets sterility assurance requirements under dynamic conditions with advanced airflow and monitoring.

Asia's growing role in the GLP-1 market presents new opportunities and challenges. Explore how regulatory preparedness, scalable manufacturing, and robust quality systems can enable growth.

Read about how natural language inputs transform into reliable analytics to help teams iterate quickly and move from concept to production‑ready dashboards without coding barriers.